A nurse is caring for a client who is receiving mydriatic eye drops. Which of the following manifestations indicates to the nurse that the client has developed a systemic anticholinergic effect?

A. Constipation: Systemic absorption of mydriatic eye drops with anticholinergic properties can reduce gastrointestinal motility, leading to constipation. This occurs because anticholinergic effects inhibit parasympathetic stimulation of the gut. Monitoring bowel habits helps identify systemic side effects early. B. Seizures: Seizures are not a common systemic effect of anticholinergic mydriatics. While serious central nervous system reactions are rare, they are not the typical manifestation of anticholinergic activity from eye drops. C. Insomnia: Insomnia may result from central nervous system stimulation, but it is less specific and less common than other anticholinergic signs. It does not directly indicate systemic anticholinergic absorption from mydriatic drops. D. Bradycardia: Anticholinergic effects typically block parasympathetic activity, which would more likely cause tachycardia rather than bradycardia. A slowed heart rate is not characteristic of systemic anticholinergic toxicity.